and it is reason to fear that increased stimulation of the EPO cell by elevated HIF due to inhibited degradation by HIF-PHI inhibitors including roxadustat, could in long-term predispose to CCRCC. The gene discussed is EPO; the disease is nonpapillary renal cell carcinoma.